Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21782681 | 0.97 | — | — | |
| SCHEMBL16768934 | 0.90 | — | — | |
| SCHEMBL16545185 | 0.79 | LMNA (0.31) | — | |
| SCHEMBL3137029 | 0.75 | — | — | |
| SCHEMBL21782682 | 0.75 | — | — | |
| SCHEMBL19971177 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL1812050 | 0.71 | — | — | |
| SCHEMBL31017583 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL8763394 | 0.71 | ALDH1A1 (0.30) | — | |
| SCHEMBL1003911 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396512-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10800783-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10766884-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3617204-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-03-04 | — | — | EP | disclosed |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10233188-B2 | CDK2/4/6 inhibitors | PFIZER INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018033815-A1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766884-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | TSHR 2494/4885CYP2C19 3286/4885 |
| US-20200354350-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | TSHR 2494/4885CYP2C19 3286/4885 |
| US-20200392142-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | TSHR 1117/4885CYP2C19 1039/4885 |
| US-11396512-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | TSHR 1070/4885CYP2C19 1040/4885 |
| US-10800783-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | TSHR 1070/4885CYP2C19 1040/4885 |
| US-20180044344-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | TSHR 1070/4885CYP2C19 1040/4885 |
| US-20190330196-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | TSHR 2494/4885CYP2C19 3286/4885 |
| US-20190135817-A1 | CDK2/4/6 Inhibitors | CDK2, CDK6, CDK20 | TSHR 1070/4885CYP2C19 1040/4885 |
| US-10233188-B2 | CDK2/4/6 inhibitors | CDK2, CDK6, CDK20 | TSHR 1070/4885CYP2C19 1040/4885 |
| US-11220494-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | TSHR 2494/4885CYP2C19 3286/4885 |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | TSHR 2494/4885CYP2C19 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.